D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Karen Kelly,John Crowley,Paul A. Bunn,Cary A. Presant,Patra K. Grevstad,Carol M. Moinpour,Scott D. Ramsey,Antoinette J. Wozniak,Geoffrey R. Weiss,Dennis F. Moore,Valerie Israel,Robert B. Livingston,David R. Gandara +12 more
TL;DR: PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer, and overall costs on the PC arm were higher than on the VC arm because of drug costs.
Journal ArticleDOI
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Kathy S. Albain,Valerie W. Rusch,John Crowley,Thomas W. Rice,Andrew T. Turrisi,James K. Weick,Vassyl A. Lonchyna,Cary A. Presant,Robert McKenna,David R. Gandara,Helen Fosmire,Sarah A. Taylor,Keith J. Stelzer,Kristen R. Beasley,Robert B. Livingston +14 more
TL;DR: The strongest predictor of long-term survival after thoracotomy was absence of tumor in the mediastinal nodes at surgery, and this trimodality approach was feasible in this Southwest Oncology Group (SWOG) study.
Journal ArticleDOI
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara,Sarah M. Paul,Marcin Kowanetz,Erica B. Schleifman,Wei Zou,Yan Li,Achim Rittmeyer,Louis Fehrenbacher,Geoff Otto,Christine Malboeuf,Daniel S. Lieber,Doron Lipson,Jacob Silterra,Lukas C. Amler,Todd Riehl,Craig Cummings,Priti S. Hegde,Alan Sandler,Marcus Ballinger,David Fabrizio,Tony Mok,David S. Shames +21 more
TL;DR: It is shown that high bTMB is a clinically actionable biomarker for atezolizumab in NSCLC, and a blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.
Journal Article
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Reginald V. Lord,Jan Brabender,David R. Gandara,Vicente Alberola,Carlos Camps,Manuel Domine,Felip Cardenal,Jose Miguel Sanchez,Paul H. Gumerlock,Miquel Taron,Jose Javier Sanchez,K. D. Danenberg,Peter V. Danenberg,Rafael Rosell +13 more
TL;DR: Everexpression of the excision repair cross-complementing 1 (ERCC1) gene is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC and the presence of weight loss were significant prognostic factors for survival in a Cox proportional hazards multivariable analysis.
Journal ArticleDOI
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
Antoinette J. Wozniak,John Crowley,Stanley P. Balcerzak,Geoffrey R. Weiss,C. Harris Spiridonidis,Laurence H. Baker,Kathy S. Albain,Karen Kelly,Sar A. Taylor,David R. Gandara,Robert B. Livingston +10 more
TL;DR: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisPlatin in the treatment of advanced NSCLC.